Prospects for targeting PD-1 and PD-L1 in various tumor types.
Immune checkpoints, such as programmed death ligand 1 (PD-L1) or its receptor, programmed death 1 (PD-1), appear to be Achilles' heels for multiple tumor types. PD-L1 not only provides immune escape for tumor cells but also turns on the apoptosis switch on activated T cells. Therapies that block this interaction have demonstrated promising clinical activity in several tumor types. In this review, we will discuss the current status of several anti-PD-1 and anti-PD-L1 antibodies in clinical development and their direction for the future.
Joseph W
JW
Kim
Joseph Paul
JP
Eder
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000032:analysis / Q000037:antagonists & inhibitors*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D009369:Neoplasms / Q000188:drug therapy*; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000032:analysis / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060890:B7-H1 Antigen; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C000594389:atezolizumab; C582435:pembrolizumab